



Dkt. No. 96700/596

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants** 

Jan Geliebter, George J. Christ, Arnold Melman, and Jamil Rehman

Serial No.

09/531,969

Filed

: March 21, 2000

For

GENE THERAPY FOR REGULATING SMOOTH MUSCLE TONE

Examiner

Peter Paras, Jr.

Group Art Unit :

1632

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

"Express Mail" mailing label No. EL 996361365 US

Date of Deposit: July 8, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450.

Name: Alan Dayliner

37 C.F.R. §1.56, applicants would

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the nine (9) references that are both listed on the attached form PTO/SB/08A-B (2 pages) and attached hereto. These references were cited in a Supplementary European Search Report issued on June 21, 2004 in connection with related European patent application No. 99942324.7. A copy of the Search Report is also attached hereto. Please note that WO 98/33529, which is also cited in the Search Report, is already of record in the subject application and is therefore not included with this Supplemental Information Disclosure Statement (SIDS).

Applicants: Jan Geliebter, et al.

Serial No.: 09/531,969

Filed : March 21, 2000

Page 2

A Request for Continued Examination (RCE) under 37 C.F.R. §1.114 was filed in the subject application on June 9, 2004. Applicants are unaware of the mailing of an Office Action after the filing of the June 9, 2004 RCE. Accordingly, pursuant to 37 C.F.R. §1.97(b)(4), no fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if a fee is required with the filing of this SIDS and/or if there are unanticipated fees required to maintain the pendency of this application, the PTO is authorized to withdraw the amount of any such fee from Deposit Account 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP

Attorneys for Applicants 90 Park Avenue

New York, New York 10016

(212) 336-8000

By:

Dated: New York, New York

July 8, 2004

Alan D. Miller, Reg. No. 42,889

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known		
Application Number	09/531,969	
Filing Date	March 21, 2000	
First Named Inventor	Jan Geliebter	
Art Unit	1632	
Examiner Name	Peter Paras, Jr.	
Attorney Docket Number	96700/596	

	U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2 (# known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US-			-		
		US-	<del>                                     </del>				
		US-					
		US-		<del></del>			
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US					
		US-					

Examiner Cite	Cite No.1	Foreign Patent Document	FOREIGN PATENT DOCU Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T <sup>6</sup>
	1	WO 98/33905	08-06-1998	Isis Innovation Ltd.		
	2	WO 97/18308	05-22-1997	The Wellcome Trust		
				Ltd. as Trustee of the		
				Wellcome Trust		
						L

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Ues	er the Paperwork Red	luction Ad	ct of 1995, no persons ar	U.S. Patent re required to respond to a collection	and Trademark Office; U.S. DEPARTMENT of information unless it contains a valid OME	OF COMMERCE 3 control number.
DENDStitute for form 1449/PTO		Complete if Known				
		Application Number	09/531,969			
INFO	ORMATION	DIS	CLOSURE	Filing Date	March 21, 2000	
STATEMENT BY APPLICANT		First Named Inventor	Jan Geliebter			
	(Use as many she	-4		Art Unit	1632	
	(USB as many sne	ets as n	ecessary)	Examiner Name	Peter Paras, Jr.	
Sheet	2	of	2	Attorney Docket Number	96700/596	

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	3	HUARD J. ET AL., entitled "Myoblast injection into the Bladder Wall: A Possible Method of Modulating Detrusor Contractility and Cell-Mediated Gene Therapy for Bladder Dysfunction," Journal of Urology, Vol. 159, No. 5, May 30, 1998., page 16,	
		XP002120829, Abstract.	
	4	CARVALHO A.C. ET AL., entitled "Gap Junctions Formed of Connexin 43 are Found Between Smooth Muscle Cells of Human Corpus Cavernosum," Journal of Urology, Vol. 149, No. 6, 1993, pgs. 1568-1575, XP002273927, Abstract.	
	5	MORENO A. P. ET AL., entitled "Gap Junctions Between Human Corpus Cavernosum Smooth Muscle Cells: Gating Properties and Unitary Conductance," American Journal of	
	6	GROSSMAN H. ET AL., entitled "Decreased Connexin Expression and Intercellular Communication in Human Bladder Cancer Cells," Cancer Research, Vol. 54, No. 11, 1994, pgs. 3062-3065.	
	7	SIEMER C. ET AL., entitled "Characterization of Maxi K Channels in Smooth Muscle Cells From Rat Urinary Bladder," Pfluegers Archiv European Journal of Physiology, Vol. 434, No. 5 Suppl., 1997, p. R102, XP008028610, Abstract.	
	8	DAMASER M. S. ET AL., entitled "Calcium Regulation of Urinary Bladder Function," Journal of Urology, Vol. 157, No. 2, 1997, pgs. 732-738, XP002282784, Abstract.	
	9	LEVIN R.M. ET AL., entitled "Etiology of Bladder Dysfunction Secondary to Partial Outlet Obstruction. Calcium Disregulation in Bladder Power Generation and the Ability to Perform Work," Scandinavian Journal of Urology and Nephrology Supplementum, Vol. 0,	
		No. 184, 1997, pgs. 43-50, XP002282785, Abstract.	

Examiner	Date	
Signature	Considered	1

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.